Antiviral drugs in the treatment of AIDS: What is in the pipeline?

European Journal of Medical Research

Volumn 12, Issue 9, 2007, Pages 483-495

  Stellbrink, Hans Jürgen ^a  

^a Infektionsmedizinisches Centrum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; AMD 070; AMD 11070; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; APRICITABINE; AVX 754; BCH 10618; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EFAVIRENZ; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GS 9137; GW 695634; INTEGRASE INHIBITOR; IPILIMUMAB; ISENTRESS; JTK 303; KP 1461; MARAVIROC; MK 0518; PPL 100; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIFUVIRTIDE; SN 1461; SPD 754; TNX 355; UK 453061; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOTHERAPY; LEUKOCYTOSIS; LIFE EXPECTANCY; LIPID BLOOD LEVEL; LIPODYSTROPHY; MENTAL DISEASE; NEUROTOXICITY; OUTCOME ASSESSMENT; SALVAGE THERAPY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 35548957272     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Palella FJJr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26;338(13):853-60.
2. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, d'Arminio MA, de WF, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 Jul 13;360(9327):119-29.
3. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, Tyrer M, Chaloner C, Wilson D, Loveday C, Johnson MA, Phillips AN. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. Aids 2001 Jan 26;15(2):185-94.
4. Cahn P, Cassetti I, Wood R, Phanuphak P, Shiveley L, Bethell RC, Sawyer J. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive,. HIV-infected patients. Aids 2006 Jun 12;20(9):1261-8.
5. Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper D. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance. 4th IAS Conference Sydney, Australia abstract WESS203. 2007.
6. Colucci P, Cottage J, Robison H, et al. Efficacy and novel pharmacology of elvucitabine in a 7 day placebo controlled monotherapy study. 46th ICAAC San Francisco abstract H-1670d. 2006.
7. Cahn P, Sosa N, Wiznia A, Patel M, Ward D, Palella F, et al. Racivir Demonstrates Safety and Efficacy in Patients Harboring HIV with the M184V Mutation and <3 TAM. 14th Conf Retro Opportun Infect Los Angeles abstract 488. 2007.
8. Pozniak A, Moraies-Ramirez J, Mohapi L, Santoscoy M, Chetchotisakd P, Hereygers M, et. al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. 14th Conf Retro Opportun Infect Los Angeles abstract 144LB. 2007.
9. Pozniak A, Steyn D, Grinsztejn B, Vinogradova E, Lupo S, Techasathit W, et al. Neuropsychiatric events with TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 4th IAS Conference Sydney, Australia abstract WEPEA105. 2007.
10. Ruxrungtham K, Bellos N, Morales-Ramirez J, Timerman A, Madruga J, Katabira E, et al. The metabolic profile of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 4th IAS Conference Sydney, Australia abstract TUAB105. 2007.
11. Lazzarin A, Campbell T, Clotet B, Johnson M, Katiama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de SG, Baeten B, Beets G, Sinha R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7;370(9581):29-48.
12. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de SG, Leopold L, Trefiglio R, Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7;370(9581):29-38.
13. Wu JJ, Stranix BR, Milot G, Ge M, Dandache S, Forté A, et al. PL-100, a Next Generation Protease Inhibitor against Drug-Resistant HIV: In Vitro and In Vivo Metabolism. 46th ICAAC San Francisco abstract H-253. 2006.
14. Wu JJ, Daigneault L, Stranix B, Ge M, Milot G, Dandache S, et al. Preclinical and Clinical Evaluation of PPL-100, a Next Generation HIV Protease Inhibitor. HIV DART Cancun, Mexico abstract 83. 2006.
15. Markowitz M, Nguyen B-Y, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid onset and durable antiretroviral effect of raltegravir (MK-0518), a novel HIV-1 integrase inhibitor, as part of combination ART in treatment HIV-1 infected patients: 48-week data. 4th IAS Conference Sydney, Australia abstract TUAB104. 2007.
16. Cooper DA, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-I Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conf Retro Opportun Infect Los Angeles abstract 105aLB. 2007.
17. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, et al. Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conf Retro Opportun Infect Los Angeles abstract 105bLB. 2007.
18. Zolopa AR, Mullen M, Berger D, Ruane P, Hawkins T, Zhong L, et al. The HIV Integrase Inhibitor GS-9137 Has Potent Antiretroviral Activity in Treatment-Experienced Patients. 14th Conf Retro Opportun Infect Los Angeles abstract 143LB. 2007.
19. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WR, Jr. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004 Jan 15;189(2): 286-91.
20. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S. TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at week 48. Int Conf Aids Toronto, Canada August 13-18 abstract ThLB0218. 2006.
21. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederost B, Weber R, Stiegler G, Katinger H, Gunthard HF, Trkola A. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007 Aug;81 (16):8793-808.
22. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 Jun;11(6):615-22.
23. Beatty J, Jacobson J, Lalezari J, Eron J, Pollard R, Saag M, et al. Safety and Antiviral Activity of PA-457, the First-In-Class Maturation Inhibitor, in a 10-Day Monotherapy Study in HIV-1 Infected Patients. 45th ICAAC Washington D.C: abstract LB-27. 2005.
24. Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C. Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers. Antimicrob Agents Chemother 2007 Sep; 51(9): 3063-6.
25. Smith P, Forrest A, Beatty J, Jacobson J, Lalezari J, Eron J, et al. Pharmacokinetics/Pharmacodynamics of PA-457 in a 10-day Multiple Dose Monotherapy Trial in HIV-infected Patients. 13th Conf Retrovir Opportun Infect abstract 52. 2006.
26. Dutschman GE, Grill SP, Gullen EA, Haraguchi K, Takeda S, Tanaka H, Baba M, Cheng YC. Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 2004 May;48(5):1640-6.
27. Medivir, Medivir. Potential nucleoside analogue drug for hepatitis B, HIV enters Phase 2 studiesManaged Care Law Weekly,2007, http://www.newsrx.com/newsletters/Managed-Care-Law-Weekly/2005-10-09/ 10032005333413MC.html
28. Bogner JR, Roecken M, Herrmann DB, Boerner D, Kaufmann B, Gurtler L, Plewig G, Goebel FD. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther 1997 Dec;2(4):257-64.
29. Bogner JR, Boerner D, Muhlhofer A, Thoma-Greber E, Herrmann DB, Hoegl L, Roecken M, Jost V, Goebel FD. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther 1997 Dec;2(4):249-56.
30. Girard PM, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, Sereni D, Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000 Mar 1;23(3):227-35.
31. Heidelberg Pharma, Clinical effectiveness and tolerability of Fosalvudine (HIV) confirmed,21-5-2007, http://www.heidelberg-pharma.com/
32. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 2005 Jul;67(1):1-9.
33. Uckun FM, DuMez D, Qazi S, Tibbles H, Venkatachalam TK. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 2007;57(2):112-21.
34. Uckun FM, Venkatachalam TK, Qazi S. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 2006 Feb;56(2A):193-203.
35. Uckun FM. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Arzneimittelforschung 2006 Feb;56(2A):121-35.
36. Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005;55(4):223-31.
37. Lennerstrand J, Bluemling G, Ruckstuhl M, Bennett M, Chu C, Schinazi R. 1-(β-D-Dioxolane) Thymine Is Effective against HIV-1-containing TAM and M184V. 13th Conf Retrovir Opportun Infect abstract 46. 2007.
38. Hernandez-Santiago BI, Chen H, Asif G, Beltran T, Mao S, Hurwitz SJ, Grier J, McClure HM, Chu CK, Liotta DC, Schinazi RF. Pharmacology and pharmacokinetics of the antiviral agent beta-D-2′,3′-dideoxy-3′-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrob Agents Chemother 2005 Jul;49(7):2589-97.
39. Yang G, Dutschman GE, Wang CJ, Tanaka H, Baba M, Anderson KS, Cheng YC. Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res 2007 Mar;73(3):185-91.
40. Tanaka H, Haraguchi K, Kumamoto H, Baba M, Cheng YC. 4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants. Antivir Chem Chemother 2005;16(4):217-21.
41. Nitanda T, Wang X, Kurnamoto H, Haraguchi K, Tanaka H, Cheng YC, Baba M. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother 2005 Aug;49(8):3355-60.
42. Nakata H, Koh Y, Kodama E, Yang G, Kohgo S, Hayakawa H, et al. Intracellular Metabolism of 2-Deoxy-4′-C-Ethynyl-2-Fluoroadenosine, a Novel 4′-C-Ethynyl Nucleoside Analog Potent against Multidrug-resistant HIV-1 Variants. 13th Conf Retrovir Opportun Infect abstract 499. 2006.
43. Waninger S, Ramos S, Robbins J. Anti-HIV-1 activity of a foscarnet analogue, synergy with zidovudine and analysis of resistance variants selected in vitro. 3rd IAS Conference Rio de Janeiro abstract TuPe6.1B16. 2005.
44. Cihlar T, Ray A, Boojamra D, Zhang L, Hui H, Grant D, et al. GS9148: A Novel Nucleotide Active Against HIV-1 Variants with Drug Resistance Mutations in Reverse Transcriptase. 13th Conf Retrovir Opportun Infect abstract 45. 2006.
45. Katlama C, Campbell T, Clotet B, Johnson M, Lazzarin A, Arasteh K, et al. DUET-2: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. 4th IAS Conference Sydney, Australia abstract WESS204-2. 2007.
46. Mills A, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Madruga JV, et al. DUET-1: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients. 4th IAS Conference Sydney, Australia abstract WESS204-1. 2007.
47. Fätkenheuer G, Staszewski S, Plettenberg A, Hackman F, Layton G, McFadyen L, et al. Short-term monotherapy with UK-453,061, a novel NNRTT, reduces viral load in HIV infected patients. 4th IAS Conference Sydney, Australia abstract WESS202. 2007.
48. Becker S. Antiviral activity and safety of GW695634, a novel next generation NNRTI in NNRTI-resistant HIV-1 infected patients. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro abstract WcPeb. 2003. 2005.
49. Eiznhamet DA, Creagh T, Ruckle JL, Tolbert DT, Giltnet J, Dutta B, Flavin MT, Jenta T, Xu ZQ. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials 2002 Nov;3(6):435-50.
50. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT, Xu ZQ. Safety and pharmaco-kinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001 May;45(5):1379-86.
51. Coulombe R, Fink D, Landry S, Lessard IAD, McCollum R, Naud J, et al. Crystallographic study with BILR 355 BS, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. 3rd IAS Conference Rio de Janeiro abstract WePp0105. 2005.
52. Antiviral Briefs. Aids Patient Care And Stds 20[12], 887-889. 2006.
53. Kodama E, Masuda N, Orita M, Yamamoto O, Fujii M, Kageyama S, et al. HIV-1 Acquires Resistance to New NNRTI, Thiazol Derivatives, through Steric Hindrance with Multiple Mutations. 12th Conf Retrovir Opportun Infect abstract 559. 2005.
54. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White FL, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG, Cho EH. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001 Feb;45(2):393-400.
55. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White EL, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG, Cho EH. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001 Feb;45(2):393-400.
56. ImQuest Pharmaceuticals, Inc, ImQuest Pharmaceuticals licenses Entire Series of Anti-HIV Therapeutic Compounds from Samjin Pharmaceutical Co.,28-2-2006, http://www.imquest.com/content_pages/File/ feb-28-samjin.pdf
57. Klumpp K, Dunn J, Heilek G, Zhou A, Stefanidis D, Chen CW, et al. R1206, a representative of a new class of potent diphenyl ether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI-resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species. Antiviral Therapy 12[S30], abstract 28. 2007.
58. Cirne-Santos CC, Teixeira VL, Barreto-de-Souza V, Castello-Branco LR, Frugulhetti ICPP, Bou-Habib DC. The Diterpene TRIOL Inhibits HIV-1 Infection mediated by Primary Isolates With Distinct Chemokine Receptor Usage. 3rd IAS Conference Rio de Janeiro abstract TuPe6.1B04. 2005.
59. Jakubik J, Seifer M, Gray L, Chapron C, Patty A, Dousson C, et al. IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz. Antiviral Therapy 12[S32], abstract 30. 2007.
60. Sevigny G, Stranix B, Tian B, Dubois A, Sauve G, Petropoulos C, Lie Y, Hellmann N, Conway B, Yelle J. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res 2006 Jun;70(2):17-20.
61. Gulnik S, Afonina E, Eissenstat M, Parkin N, Japour A, Erickson J. SPI-256, a Highly Potent HIV Protease Inhibitor with Broad Activity against MDR Strains. 13th Conf Retrovir Opportun Infect abstract 501. 2007.
62. Afonina E, Gulnik S, Eissenstat M, Yokoe H, Yu B, Parkin NT, et al. Higly Potent Protease Inhibitors with Novel Escape Pathways. Antiviral Therapy 12[S21], abstract 19. 2007.
63. Koh Y, Nakata H, Ogata-Aoki H, Nakayama M, Leschenko S, Ghosh A, et al. Determination of Resistance Profile of GRL-02031, a Novel Nonpeptidic Protease Inhibitor Containing a Cyclopentanyltetrahydrofuran Moiety. 13th Conf Retrovir Opportun Infect abstract 503. 2006.
64. Koh Y, Nakata H, Ogata-Aoki H, Leschenko S, Ghosh A, Mitsuya H. UIC-02031: A Novel Nonpeptidic Protease Inhibbitor Containing a Stereochemically Defined Fused Cyclopentanyltetrahydroffuran Potent against Multi-PT-Resistant HIV-1 in vitro. 12th Conf Retrovir Opportun Infect abstract 562. 2005.
65. Bristol-Myers Squibb, Trial Details for Trial AI441-008,24-8-2007, http://ctr.bms.com/ctd/InitTrialDetailAction.do?pnum=AI441-008
66. Reddy S, Min S, Borland J, Song I, Lin J, Mehta A, et al. A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy Subjects (GRZ105655). 14th Conf Retro Opportun Infect Los Angeles abstract 562. 2007.
67. China Daily, Human trials begin for anti-HIV drug,23-2-2006, http//www.chinadaily.com.cn/english/doc/2006-02/23/content_523134.htm
68. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003 Nov 11;100(23):13555-60.
69. McCallister S, Doto J, Allaway G, Martin DE. Multiple dosing of the novel HIV-1 maturation inhibitor bevirimat (BVM): aggregate adverse event (AE) and laboratory data from four short-term studies. 4th IAS Conference Sydney, Australia abstract WEPEA110. 2007.
70. Kilgore N, Reddick M, Zuiderhof M, Stanley D, Nitz T, Bullock P, et al. Characterization of PA1050040, a second generation HIV-1 maturation inhibitor. 4th IAS Conference Sydney, Australia abstract MOPDX05. 2007.
71. Blair W, Cao J, Jackson L, Peng Q, Isaacon J, Butler S, et al. Execution of a High Throughput HIV-1 Replication Screen and the Identification of a Novel Small Molecule Inhibitor that Targets HIV-1 Envelope Maturation. 13th Conf Retrovir Opportun Infect, abstract 50 LB. 2006.
72. Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RWJ, Covell DG, Wallqvist A, McDonnell NB, DeGuzman RN, Summers MF, Zalkow L, Bader JP, Haugwitz RD, Sausville EA. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997 Mar;3(3):341-5.
73. Goebel FD, Hemmer R, Schmit JC, Bogner JR, De CE, Witvrouw M, Pannecouque C, Valeyev R, Vandevelde M, Margery H, Tassignon JP. Phase I/ II dose escalation and randomized withdrawal study with add-on azodicar-bonamide in patients failing on current antiretroviral therapy. Aids 2001 Jan 5;15(1):33-45.
74. H-Phar, An open, single-dose, two ways cross-over, food interaction study to assess the safety, bioavailability and pharmacokinetics of HPH116,2007, http://www.h-phar.com/News.php
75. Medivir AB Sweden, press release,20-12-2006, http://www.medivir.se/v3/se/ ir_media/press_releases.aspx?id=137
76. Ehtesvami M, Deval J, Barry S, Jochmans D, Hertogs K, Götte M. Nucleotide-competing Reverse Transcriptase Inhibitors form a Stable Dead-end Complex with the HIV-1 Enzyme. 13th Conf Retrovir Opportun Infect abstract 47. 2006.
77. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006 Jun;50(6):2231-3.
78. Tanaka Y, Okuma K, Tanaka R, Kumakura S, Shimoyamada A, Hirose K, et al. Development of Novel Orally Bioavailable CXCR4 Antagonists, KRH-3955 and KRH-3140: Binding Specificity, Pharmacokinetics and Anti-HIV-1 Activity in vivo and in vitro. 13th Conf Retrovir Opportun Infect abstract 49LB. 2006.
79. Schurmann D, Fatkenheuer G, Reynes J, Michelet C, Raffi F, van LJ, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. Aids 2007 Jun 19;21(10):1293-9
80. Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Godfrey C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. 4th IAS Conference Sydney, Australia abstract TUAB102. 2007.
81. Cohen C, DeJesus E, Mills A, Pierone Jr. G, Kumar P, Ruane P, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy. 4th IAS Conference Sydney, Australia abstract TUAB106. 2007.
82. Saag MS, Jacobson JM, Thompson M, Fischl M, Liporace R, Reichman RC, et al. Antiviral effects and tolerability of the CCR5 monoclonal antibody PRO 140: a proof of concept study in HIV-infected individuals. 4th IAS Conference Sydney, Australia abstract WESS201. 2007.
83. Giguel F, Beebe L, Migone TS, Kuritzkes D. The anti-CCR5 mAb004 inhibits hiv-1 replication synergistically in combination with other antiretroviral agents but does not select for resistance during in vitro passage. 13th Conf Retrovir Opportun Infect abstract 505. 2006.
84. Jekle A, Kondru R, Ki C, Chuang KT, Swinney DC, Rotstein D, et al. CCR5 binding properties of a CCR5 small-molecule-inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain. Antiviral Therapy 12[S13], abstract 11. 2007.
85. Schols D, Vermeire K, Fransen S, Huang W, Toma J, Whitcomb J, et al. Multi-drug Resistant HIV-1 Is Sensitive to Inhibition by Chemokine Receptor Antagonists. 12th Conf Retrovir Opportun Infect abstract 545. 2005.
86. Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005 Nov;49(11):4584-91.
87. Moyle G, DeJesus E, Boffito M, Wong R, Coakley E, Gibney C, et al. CXCR4 Antagonism: Proof of Activity with AMD11070. 14th Conf Retro Opportun Infect Los Angeles abstract 511. 2007.
88. Saag M, Rosenkranz S, Becker S, Klingman K, Kallungal B, Zadzilka A, et al. Proof of Concept of Antiretroviral Activity of AMD11070 (an Orally Administered CXCR4 Entry Inhibitor): Results of the First Dosing Cohort A Studied in ACTG Protocol A5210. 14th Conf Retro Opportun Infect Los Angeles abstract 512. 2007.
89. Murakami T, Yoshida A, Tanaka R, Mitsuhashi S, Hirose K, Yanaka M, et al. KRH-2731: An Orally Bioavailable CXCR4 Antagonist Is a Potent Inhibitor of HIV-1 Infection. 11th Conf Retrovir Opportun Infect abstract 541. 2004.
90. Castagna A, Biswas F, Beretta A, Lazzarin A. The Appealing Story of HIV Entry Inhibitors: From Discovery of Biological Mechanisms to Drug Development. Drugs 65[7], 879-904. 2005.
91. Zhang U. A bis-azo-dye (FP-21399) inhibits HIV-1 replication in the post-absorption stage. 4Th Conf Retro And Opportun Infect 1997 Jul;104(abstract no. 217):no-26.
92. Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study. J Infect Dis 2000 Aug;182(2):607-10.
93. Poli G, Vicenzi E. FP-21399 (Lexigen Pharmaceuticals). IDrugs 2001 Nov;4(11):1293-5.
94. Dai SJ, Dou GF, Qiang XH, Song HF, Tang ZM, Liu DS, Liu XW, Yang LM, Zheng YT, Liang Q. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005 Oct;26(10):1274-80.
95. FusoGen, Sifuvirtide,2007, http://www.fusogen.com/en/lm3-1.asp
96. Trimeris, Pipeline. Next-Generation Fusion Inhibitors, 2007, http://www.trimeris.com/330NextGeneration.aspx
97. Ambrilia Biopharma, HIV/AIDS - SPC3,2007, http://www.ambrilia.com/en/ products/hiv-aids-spc3.php
98. Samaritan Pharmaceuticals, Samaritan Partnered Its Phase II SP-01A HIV Drug to Pharmaplaz, Ireland,28-8-2007, http://www.samaritanpharma.com/ aids_hiv_program_sp-01a.asp
99. Wang X, Douglas SD, Lai J-P, Tuluc F, Tebas P, Ho W. Neurokinin-1 Receptor Antagonist (Aprepitant) Inhibits Drug-Resistant HIV-1 Infection of Macrophages in vitro. Journal of NeuroImmune Pharmacology 2007 Jan 12;2(1):1557-904.
100. Munch J, Standker L, Adetmann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007 Apr 20;129(2):263-75.
101. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007 Aug;7(8):1245-56.
102. Medarex, Medarex Initiates Phase I Clinical Trial of MDX-010 in HIV,11-6-2007, http://www.medarex.com/cgi-local/item.pl/20030611-555575
103. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, Hatter T, Hauber J. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005 Jan;115(1):76-85.
104. Haffar O, Dubrovsky L, Bukrinsky M. Oxadiazols: a new class of rationally designed anti-HIV compounds targeting nuclear localization signal of the viral matrix protein. 3rd IAS Conference Rio de Janeiro abstract TuPe6.1B01. 2005.
105. Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, Burns EM, Dixon JD, O'Loughlin C, Williams LA, Pickering PJ, Crumpacker CS, Gelder FB. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis 2003 Feb 1;187(3):500-3.
106. Sanford J, Dezube B, Perera T, Crumpacker C, Gelder F. Polyclonal Caprine IgG PEHRG214 (HRG); Anti-HIV Activity and Mapping of Novel Antibody Specificities. 3rd IAS Conference Rio de Janeiro abstract WePe 6.2C02. 2005.
107. Yoshimura K, Shibata J, Honda A, Murakami T, Mitsuya H, Koito A, et al. Resistance Profile of a Novel Broadly Neutralizing Anti-HIV Monoclonal Antibody, KD-247, that Has Favorable Synergism with Anti-CCR5 Inhibitors in vitro. 13th Conf Retrovir Opportun Infect #506. 2006.